Kintor’s KX-826 meets phase III endpoints in alopecia
Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the pr...
Publisher
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the pr...
Source route
Continue on bioworld.com
Leave the platform to read the original full article on the publisher site.
Source: BioWorld NMPA RSS
Scope: Regulatory
Related coverage
More related coverage
Reviews and Related Services
医薬品・医療機器・再生医療等製品の承認審査・安全対策・健康被害救済の3つの業務を行う組織。
24 March 2026News releaseWHO recommends new diagnostic tools to help end TB
On World TB Day, the World Health Organization (WHO) is urging countries to accelerate action to end...
24 March 2026Departmental updateStrengthening digital health capacities through blended learning
In many low- and middle-income countries, national digital health teams face a familiar reality: fra...
What's new
Evaluation, supervision and safety monitoring of medicines in the EU.